

1 A rare haplotype of the *GJD3* gene 2 segregating in familial Meniere Disease 3 interferes with connexin assembly

4 Alba Escalera-Balsera^{1,2,3}, Paula Robles-Bolivar^{1,2,3}, Alberto M. Parra-Perez^{1,2,3}, Silvia Murillo-
5 Cuesta^{4,5,6}, Han Chow Chua⁷, Lourdes Rodríguez-de la Rosa^{4,5,6}, Julio Contreras^{5,6,8}, Ewa Domarecka⁹,
6 Juan Carlos Amor-Dorado¹⁰, Andrés Soto-Varela^{11,12}, Isabel Varela-Nieto^{4,5,6}, Agnieszka J Szczypek⁹,
7 Alvaro Gallego-Martinez^{1,2,3}, Jose A. Lopez-Escamez^{1,2,3,14}

8 ¹ Otolaryngology & Neurotology Group CTS495, Instituto de Investigación Biosanitaria, ibs.GRANADA,
9 Universidad de Granada, 18071 Granada, Spain

10 ² Division of Otolaryngology, Department of Surgery, Universidad de Granada, Granada, Spain

11 ³ Sensorineural Pathology Programme, Centro de Investigación Biomédica en Red en Enfermedades
12 Raras, CIBERER, Madrid, Spain

13 ⁴ Institute for Biomedical Research Sols-Morreale (IIBm), Spanish National Research Council-
14 Autonomous University of Madrid (CSIC-UAM), Madrid, Spain

15 ⁵ Rare Diseases Networking Biomedical Research Centre on Rare Diseases (CIBERER), Carlos III
16 Institute of Health, Madrid, Spain

17 ⁶ La Paz Hospital Institute for Health Research (IdiPAZ), Madrid, Spain

18 ⁷ Sydney Pharmacy School, Faculty of Medicine and Health and Charles Perkins Centre, The University
19 of Sydney, Sydney, New South Wales, Australia

20 ⁸ Anatomy and Embryology Department, Faculty of Veterinary, Universidad Complutense de Madrid,
21 Madrid, Spain

22 ⁹ Department of Otorhinolaryngology, Head and Neck Surgery, Charité-Universitätsmedizin Berlin,
23 Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1,
24 10117 Berlin, Germany

25 ¹⁰ Department of Otolaryngology, Hospital Can Misses, Ibiza, Spain

26 ¹¹ Division of Otoneurology, Department of Otorhinolaryngology, Complejo Hospitalario
27 Universitario, Santiago de Compostela, Spain

28 ¹² Department of Surgery and Medical-Surgical Specialities, Universidade de Santiago de Compostela,
29 Santiago de Compostela, Spain

30 ¹³ Meniere's Disease Neuroscience Research Program, Faculty of Medicine & Health, School of
31 Medical Sciences, The Kolling Institute, University of Sydney, Sydney, New South Wales, Australia

32 Correspondence:

33 Prof. Jose A. Lopez-Escamez

34 Meniere's Disease Neuroscience Research Program,

35 Faculty of Medicine & Health, School of Medical Sciences, University of Sydney,

36 The Kolling Institute,

37 10 Westbourne St, St Leonards NSW 2064

38 Sydney

39 Australia

40 E-mail: jose.lopezescamez@sydney.edu.au

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

41 Abstract

42 Familial Meniere Disease (FMD) is a rare polygenic disorder of the inner ear. Mutations in the connexin
43 gene family, which encodes gap junction proteins, can also cause hearing loss, but their role in FMD is
44 largely unknown. Here, we found an enrichment of rare missense variants in the *GJD3* gene when
45 comparing allelic frequencies in FMD (N=94) with the Spanish reference population (OR=3.9[1.92-
46 7.91], FDR=2.36E-03). In the *GJD3* sequence, we identified a rare haplotype (TGAGT) composed of
47 two missense, two synonymous, and one downstream variants. This haplotype was found in five
48 individuals with FMD, segregating in three unrelated families with a total of ten individuals; and in
49 another eight Meniere Disease individuals. *GJD3* encodes the gap junction protein delta 3, also known
50 as human connexin 31.9 (CX31.9). The protein model predicted that the NP_689343.3:p.(His175Tyr)
51 missense variant could modify the interaction between connexins and the connexon assembly, affecting
52 the homotypic GJD3 gap junction between cells. Our studies in mice revealed that the mouse ortholog
53 *Gjd3* - encoding Gjd3 or mouse connexin 30.2 (Cx30.2) - was expressed in the organ of Corti and
54 vestibular organs, particularly in the tectorial membrane, the base of inner and outer hair cells and the
55 nerve fibers. The present results describe a novel association between *GJD3* and familial FMD,
56 providing evidence that FMD is related to changes in the inner ear channels; in addition, it supports a
57 new role of tectorial membrane proteins in FMD.

58 Keywords

59 Meniere Disease; Hearing loss; Inner ear; Tectorial membrane; Exome sequencing; Bioinformatics;
60 Connexin gene; Connexin protein; Protein modeling; Immunohistofluorescence.

61 1. Introduction

62 Connexins are essential plasma membrane proteins in epithelial intercellular junctions ¹. Connexin
63 protein subunits form a hexameric complex named connexon, and each connexon forms a hemichannel
64 in the plasma membrane. The arrangement of two connexons between adjacent cells forms a gap
65 junction, which communicates the cytoplasm of both cells and controls the intercellular exchange of
66 small molecules, metabolites and ions ^{2,3}. In the inner ear, gap junctions are essential in maintaining the
67 fluid's homeostasis. They are located in the organ of Corti and the lateral wall of the cochlea, including
68 the stria vascularis ^{2,4,5}.

69 The tectorial membrane (TM) is an extracellular matrix located along the length of the organ of Corti,
70 where the lateral surface is attached to the stereocilia of the mechanosensory hair cells. It intercedes in
71 the deflection of the stereocilia, being involved in the hair cell stimulation and, therefore, in the gating
72 of channels ^{6,7}.

73 Meniere Disease (MD, MIM: 156000) is an inner ear disorder characterized by episodic vertigo and
74 associated with sensorineural hearing loss (SNHL), tinnitus and/or aural fullness ⁸. The criteria to
75 diagnose MD are based on the clinical symptoms occurring during the attacks of vertigo and the
76 documentation of SNHL by pure tone audiogram before, during, or after the episode of vertigo. Several
77 subgroups of patients with MD have been reported according to associated co-morbidities ⁹, such as
78 migraine or autoimmune disorders, cytokine profile ¹⁰ or methylation signature ¹¹.

79 The syndrome shows familial aggregation and several rare variants in different genes have been
80 reported in singular families, manifesting a considerable genetic heterogeneity ¹². Furthermore, exome
81 sequencing in additional families with MD supports a burden of rare variation in three central SNHL
82 genes in familial MD (FMD), including *OTOG* (MIM: 604487) ¹³, *MYO7A* (MIM: 276903) ¹⁴ and
83 *TECTA* (MIM: 602574) ¹⁵.

84 Furthermore, genetic studies have demonstrated the importance of some connexins expressed in the
85 inner ear for human hearing. *GJB2* (MIM: 121011) mutations lead to approximately half of monogenic
86 non-syndromic SNHL, besides *GJB6* (MIM: 604418) and *GJB3* (MIM: 603324) mutations cause non-
87 syndromic HL ^{2,3}. In this way, Gallego-Martinez et al. ¹⁶ found a significant overload of missense
88 variants in *GJB2* in sporadic MD (SMD) patients that were not found in the reference population.

89 We have sequenced and analyzed a large cohort of patients with MD and identified a rare haplotype
90 TGAGT in the gene *GJD3* (MIM: 607425), segregating the phenotype in multiple families, supporting
91 *GJD3* as a new gene associated with FMD.

92 2. Materials and methods

93 2.1. Patient selection

94 Patients were diagnosed as definite MD according to the diagnostic criteria described by the
95 International Classification Committee for Vestibular Disorders of the Barany Society ¹⁷. A total of 94
96 FMD patients from Spanish referral centers belonging to 70 different families with one or more first-
97 degree relatives affected by MD were included. In addition, a dataset of 313 patients with SMD was
98 studied. Pure-tone audiograms were retrieved to assess hearing loss (HL), and audiometry was
99 represented using tidy^r ¹⁸, ggplot2 ¹⁹, dplyr ²⁰, ggpubr ²¹, scales ²² R packages.

100 The human ethics protocol of this study was approved by the Institutional Review Board (Protocol
101 number: 1805-N-20), and all the subjects signed a written informed consent to donate biological
102 samples. The animal experiments were approved by the Governmental Ethics Commission for Animal
103 Welfare in Berlin, Germany (LaGeSo Berlin, Germany; approval number: T 0235/18) and by the
104 Dirección General de Agricultura, Ganadería y Alimentación in Comunidad de Madrid, Spain (approval
105 number PROEX 325.4/21). The investigation followed the principles of the Declaration of Helsinki
106 revised in 2013 ²³.

107 2.2. Exome sequencing

108 To perform WES, blood samples were obtained from each patient. DNA samples were extracted using
109 prepIT-L2P (DNA Genotek, Ottawa, Canada) and QIAamp DNA Mini Kit (Qiagen, Venlo, The
110 Netherlands) following manufacturer's protocols. The quality controls required for exome sequencing
111 were performed as previously described ²⁴. DNA libraries were prepared to select coding regions by
112 using SureSelect Human All Exon V6 capture kit (Agilent Technologies, Santa Clara, CA, USA) and
113 paired-end sequenced on the Illumina HiSeq 4000 platform with a mean coverage of 100X.

114 2.3. Dataset generation

115 Paired-end sequences were mapped to the GRCh38/hg38 human reference genome, using the maximal
116 exact matches algorithm Burrows-Wheeler Aligner. Nextflow Sarek v2.7.1 workflow, included in nf-
117 core ²⁵, was utilized to perform the exome reference alignment, base quality score recalibration (BSQR),
118 variant calling, and quality filtering. Duplicated reads were removed, and the alignment quality was
119 evaluated ²⁶. Genetic variants were called using the Haplotypecaller function, from GATK ²⁷. In this
120 stage, Single Nucleotide Variants (SNVs) and short insertions and deletions (indels) were detected at
121 nucleotide resolution, and the results were saved in a Variant Calling Format (VCF) file for each subject.

122 The VCF files were normalized with the norm function from bcftools ²⁸. Each VCF file was filtered
123 according to the criteria followed to create the gnomAD database: Allele balance (AB) ≥ 0.2 and $AB \leq$

124 0.8 (for heterozygous genotypes only), genotype quality (GQ) ≥ 20 , and depth (DP) ≥ 10 (5 for haploid
125 genotypes on sex chromosomes) ²⁹. Using the merge function of bcftools, a MD variant dataset
126 containing the variants of all the individuals was generated ²⁸. Following GATK best practices, a variant
127 quality filtering was carried out with Variant Score Recalibration (VQSR), which calculates a new
128 quality score: VQSLOD. Variants that accomplished a VQSLOD < 90 were retained.

129 2.4. Variant annotation and prioritization strategy

130 Variants included in the dataset were annotated using Ensembl Variant Effect Predictor (VEP). Then,
131 variants in connexin genes for SMD and FMD were selected and saved separately for further analyses
132 ^{3,30}.

133 Two independent databases were used to retrieve the allelic frequencies (AF) of the variants in three
134 reference populations. The AF for Non-Finish European (NFE, n = 32,299) and global population (n =
135 71,702) were obtained from the gnomAD database v.3.0 ²³. Population-specific AF for the Spanish
136 population were retrieved from the Collaborative Spanish Variant Server (CSVS, n = 2,048) ³². For this,
137 we performed a liftover from GRCh19/hg19 to GRCh38/hg38 reference genomes, which only included
138 SNVs.

139 To perform the Gene Burden Analysis (GBA), an AF < 0.05 was selected as a threshold in the three
140 databases. Besides, variants were classified according to the consequence in the protein to perform 6
141 different GBA (missense; frameshift, inframe deletion and inframe insertion; stop gain; 3'UTR; 5'UTR;
142 and synonymous) for familial patients (Figure S1). Only one individual from each family was selected,
143 whenever possible, according to the lowest age of onset and/or from the last generation.

144 To search genes associated with FMD, a GBA was carried out in familial cases. The aggregated AF for
145 each gene calculated for the three reference populations (gnomAD NFE, gnomAD global and CSVS)
146 was compared with the aggregated AF in FMD, and odds ratios (OR) with 95% confidence interval (CI)
147 were calculated. Furthermore, two-sided p-values were obtained and corrected according to the False
148 Discovery Rate (FDR) for multiple testing by the total number of variants identified for each gene; and
149 Etiological Fraction (EF) was calculated, as previously described ³³. Genes with an adjusted p-value $<$
150 0.05 and OR ≥ 1 in one of the three comparisons with each reference population were considered
151 enriched.

152 To prioritize those genes obtained as enriched in the GBA, the dataset RNA-Seq in P0 from the murine
153 cochlea to contrast HC with the rest of the cochlear duct from the gene Expression Analysis Resource
154 (gEAR) database ³⁴ was used. Genes expressed in the inner ear were selected for further analysis.
155 Variants in selected genes were assessed by the Combined Annotation Dependent Depletion (CADD)

156 ³⁵ score and following the standards and guidelines described by the American College of Medical
157 Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) ³⁶.

158 Visual inspection confirmed candidate variants in BAM files to rule out false positives. Moreover, the
159 variants NC_000017.11:g.40363293G>A, NC_000017.11:g.40363579G>T and
160 NC_000017.11:g.40363294C>G in *GJD3* were validated by Sanger sequencing, using the following
161 primers: CCACCGCGAAATAGAAGAGC (Fw) and AGGACGAGCAAGAGGAGTTC (Rv).

162 The constraint metrics were obtained from the gnomAD database v.2.1.1 ³¹. The ratio of the
163 observed/expected missense variants and the Z score were calculated with the deviation of observed
164 from the expected were considered in this study. A Z score calculated by the ratio between observed
165 variation and expected depletion of variation at a 1kb scale.

166 2.5. Linkage disequilibrium and haplotype

167 The complete list of *GJD3* variants was downloaded from gnomAD database v.3.1.2 ³¹ to calculate the
168 linkage disequilibrium (LD) among all known variants in *GJD3*. The R^2 score was obtained and
169 represented for each pair of variants, using the *LDmatrix* and *LDheatmap* function from the LDlinkR ³⁷
170 and LDheatmap ³⁸ R packages, respectively. Besides, the *LDhap* function from the LDlinkR R package
171 was used to calculate the haplotype frequencies of shared variants in the global (ALL), European (EUR)
172 and Iberian in Spain (IBS) populations. Population genotype data used in LDlinkR was obtained from
173 Phase 3 (Version 5) of the 1,000 Genomes Project.

174 2.6. Computational protein modeling

175 The GJD3 amino acid sequence was retrieved from Uniprot (Q8N144). The monomer structural model
176 was predicted using AlphaFold2 ³⁹. The structural model of the homomeric connexon, with a C6
177 symmetry, and the homotypic gap junction (two connexons) was predicted using HDOCK ⁴⁰. HDOCK
178 does not use the entire protein in the docking process, focusing on predicting the conformation of the
179 binding sites of the protein to reduce the computational cost. The quality of the protein structural models
180 was assessed using the structure validation algorithms Molprobit ⁴¹, Verify3D ⁴², ERRAT ⁴³, ProSA-
181 web ⁴⁴, and QMEANDisCo ⁴⁵. The mutated GJD3 protein was modeled by comparative homology
182 modeling with MODELLER 10.4 ⁴⁶ using the wild-type GJD3 protein model as a template. These in-
183 silico models were used to predict the protein stability change ($\Delta\Delta G$) caused by the candidate variants,
184 using the ENCoM ⁴⁷, DynaMut2 ⁴⁸, I-Mutant ⁴⁹, mCSM ⁵⁰, mCSM-membrane ⁵¹, mmCSM-PPI ⁵², SDM
185 ⁵³ and, PremPS ⁵⁴ tools. Variants were classified as neutral when $-0.5 < \Delta\Delta G_{\text{pred}} < 0.5$ ⁵⁵.

186 The GJD3 structural model was submitted to the ModelArchive database
187 (<https://modelarchive.org/doi/10.5452/ma-bwdwf>; Public access after publication. Temporary access
188 code: Uy6tl2t305).

189 2.7. Mouse cochlear RNA Isolation and quantitative RT-PCR

190 Cochlear samples from C57BL/6JCrI mice of 1, 6 and 12 months of age were obtained and processed
191 as reported ^{56,57}. Immediately after dissection, cochleae were frozen in RNAlater® solution (Ambion,
192 Foster City, CA, USA). Cochlear RNA was extracted using the RNeasy Plus Mini kit (Qiagen, Hilden,
193 Germany) automated on the Qiacube (Qiagen, Hilden, Germany). RNA integrity was assessed with an
194 Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). cDNA was generated from
195 pooled cochlear RNA extracts (each pool included three cochleae from different animals per age group)
196 by reverse transcription with the High-Capacity cDNA Reverse Transcription Kit (Applied
197 Biosynthesis, Thermo Fisher Scientific) and amplified in triplicate by real time quantitative PCR (RT-
198 qPCR) in a QuantStudio 7 Flex PCR System (Applied Biosystems, Foster City, CA, USA) using gene-
199 specific primers (Fw: CGCACACGGTCTCGACTGTTT, Rv: GCGAAGTAGAAGACCACGAAGAC).
200 Data was collected after each amplification step and analyzed with QuantStudio™ Real-Time PCR
201 software 1.3 (Applied Biosystems). *Hprt1* (hypoxanthine phosphoribosyltransferase 1) and *Tbp*
202 (TATA-Box Binding Protein) genes were used as housekeeping genes for normalization. Differences
203 between ages were calculated by the Student's t-test with Δ Ct values (Ct target gene - Ct value reference
204 gene), and the Fold Change (FC) and Standard error of the mean (SEM) were obtained following the 2-
205 $\Delta\Delta$ CT method. Outliers were identified by the interquartile range (IQR) method filtering those values 1.5
206 IQR below the first quartile or 1.5 IQR above the third quartile. The statistics and visualizations were
207 performed using ggplot2 ¹⁹ and ggpubr ²¹ R packages.

208 2.8. Mouse cochlear Immunohistofluorescence

209 Cochlear samples from postnatal day 3 (P3), postnatal day 30 (P30), and postnatal day 90 (P90)
210 C57BL/6JCrI mice were obtained and processed following standard protocols, as reported ^{56,57}. Briefly,
211 adult mice were perfused with 4% paraformaldehyde in PBS. Dissected inner ears were post-fixed with
212 4% paraformaldehyde, decalcified in 5% EDTA, cryopreserved with sucrose and embedded in a
213 medium for cryotomy. For immunostaining, cryostat cross sections (10 μ m) were firstly dried at room
214 temperature and then washed with PBS 0.1 M. After that, specimens were incubated for 1 hour in a
215 normal goat serum solution in a humidified chamber at room temperature to block nonspecific binding
216 sites. Then the specimens were incubated for 24 hours with primary antibody (rabbit polyclonal anti-
217 Connexin 30.2, LifeTechnologies, # 40-7400) diluted (1:125) in goat serum/PBS/Triton X-100 at 4°C
218 in a humidified chamber. On the following day, after 4x 15 minutes of washing, specimens were
219 incubated with the specific fluorophore-conjugated antibody (Alexa Fluor 488 Goat Anti-Rabbit IgG
220 (H+L), LifeTechnologies, # A11034) diluted (1:400) in goat serum/PBS/Triton X-100 for 1.5 hours at
221 room temperature in a humidified chamber. Finally, the specimens were coverslipped using ProLong®
222 Gold Antifade Reagent with DAPI (Cell Signaling Technologies, Danvers, MA, USA, # 8961). The
223 fluorescent images of stained cryosections from P90 mice were taken with an epifluorescence

224 microscope (Nikon 90i, Tokyo, Japan); and from P3 and P30 mice with a Leica SPE confocal
225 microscope. The confocal images were merged in a z-stack using ImageJ⁵⁸.

226 2.9. Functional validation in *Xenopus* oocytes

227 Human CX31.9 wild-type (WT), NP_689343.3:p.(His175Tyr) and NP_689343.3:p.(Arg253Pro)
228 complementary DNAs (cDNAs) cloned between NheI and BamHI sites in a modified pCDNA3.1(+)
229 vector containing 5' and 3'-*Xenopus* globin UTR and a polyadenylation signal, were generated using
230 custom gene synthesis with codon optimization for *Homo sapiens* (GenScript). For expression in
231 *Xenopus laevis* oocytes, plasmid DNAs were linearized with BamHI restriction enzyme, from which
232 capped RNAs were synthesized using the T7 mMessage mMachine Kit (Invitrogen).

233 Oocyte extraction from *Xenopus laevis* frogs was performed following a protocol approved by the
234 Animal Ethics Committee of The University of Sydney (AEC No. 2016/970) in accordance with the
235 National Health and Medical Research Council of Australia code for the care and use of animals.
236 Ovarian lobes were sliced into small pieces using surgical knives and defolliculated by collagenase
237 treatment. Healthy-looking stage V-VI oocytes were injected with 50 nL of a 0.5 ng/nL RNA and
238 incubated at 18 °C in modified Barth's solution (96 mM NaCl, 2.0 mM KCl, 1 mM MgCl₂, 1.8 mM
239 CaCl₂, 5 mM HEPES, 2.5 mM sodium pyruvate, 0.5 mM theophylline, and 100 µg/mL gentamicin;
240 pH 7.4). Two to three days after RNA injection, two-electrode voltage-clamp measurements were
241 performed on oocytes continuously perfused in recording solution mimicking the endolymph (100 mM
242 KCl, 2 NaCl, 1.8 mM BaCl₂, 5 mM HEPES; pH 7.4) at room temperature using an Axon GeneClamp
243 500B amplifier (Molecular Devices, LLC, Sunnyvale, CA, USA). Data were acquired using the
244 pCLAMP 10 software (Molecular Devices) and a Digidata 1440A digitizer (Molecular Devices),
245 sampled at 10 kHz. Recording microelectrodes with resistances around 0.2–1.0 MΩ were pulled from
246 borosilicate glass capillaries (Harvard Apparatus) using a PC-100 Dual-Stage Glass Micropipette Puller
247 (Narishige) and were filled with 3 M KCl.

248 3. Results

249 3.1. Overload of missense variants in the *GJD3* gene in familial cases

250 A total of 71 variants in 19 connexin genes with an AF < 0.05 were retained to carry out a GBA in FMD
251 individuals (Table 1, Figure S1, Table S1). Variants were classified according to the consequence in
252 the protein, the most common being missense variants. We found an enrichment of missense variants
253 in the *GJD3* gene when comparing the AF in FMD against the Spanish population from CSVS (OR =
254 3.9 [1.92-7.91], FDR = 2.36E-03, EF = 0.74). Moreover, an enrichment of synonymous variants in the
255 *GJD3* gene comparing the AF in the FMD against the Spanish population from CSVS (OR = 3.46 [1.89-
256 6.33], FDR = 5.76E-04, EF = 0.71), and also the global population from gnomAD (OR = 2.9 [1.63-
257 5.14], FDR = 3.02E-03, EF = 0.65).

258 **Table 1.** Connexins genes with enrichment of rare variants (Allelic Frequency (AF) < 0.05) in Familial Meniere Disease (FMD).

Consequence(s)	Gene symbol	Protein	Number variants	Number individuals	gnomAD NFE			gnomAD			CSVS		
					OR [CI]	FDR	EF	OR [CI]	FDR	EF	OR [CI]	FDR	EF
Missense	<i>GJA1</i>	CX43	1	5	2.36 [0.96-5.78]	8.99E-01	0.58	4.15 [1.7-10.15]	2.75E-02	0.76	2.12 [0.84-5.34]	> 1	0.53
	<i>GJA3</i>	CX46	3	4	4.43 [1.65-11.91]	4.79E-02	0.77	5.83 [2.17-15.65]	7.00E-03	0.83	6.71 [2.26-19.91]	8.48E-03	0.85
	<i>GJA5</i>	CX40	1	1	28.12 [3.72-212.83]	1.85E-02	0.96	39.3 [5.3-291.32]	4.92E-03	0.97	2.51 [0.32-19.42]	> 1	0.60
	<i>GJA10</i>	CX62	1	1	159.42 [16.48-1542.37]	1.78E-04	0.99	265.31 [29.46-2389.29]	9.69E-06	1.00	-	-	-
	<i>GJB5</i>	CX31.1	3	3	102.47 [29.34-357.95]	6.04E-12	0.99	3.6 [1.15-11.22]	4.11E-01	0.72	12.65 [3.26-49.08]	3.43E-03	0.92
	<i>GJB7</i>	CX25	1	1	15.42 [2.09-113.78]	1.09E-01	0.94	20.4 [2.8-148.64]	4.38E-02	0.95	5.86 [0.68-50.52]	> 1	0.83
	<i>GJD3</i>	CX31.9	2	5	1.45 [0.75-2.82]	> 1	0.31	2.19 [1.13-4.26]	3.10E-01	0.54	3.9 [1.92-7.91]	2.36E-03	0.74
Frameshift, inframe deletion and insertion	<i>GJD3</i>	CX31.9	1	1	473.13 [29.44-7603.58]	4.14E-05	1.00	69.73 [9.15-531.62]	1.26E-04	0.99	-	-	-
3'UTR	<i>GJC3</i>	CX30.2	1	1	-	-	-	-	-	-	29.46 [1.83-473.51]	1.70E-02	0.97
Synonymous	<i>GJA4</i>	CX37	1	1	-	-	-	1061.55 [66.06-17059.72]	9.63E-06	1.00	-	-	-
	<i>GJB3</i>	CX31	2	1	13.66 [3.33-55.97]	2.81E-03	0.93	0.29 [0.07-1.18]	9.32E-01	-2.40	3.35 [0.77-14.49]	> 1	0.70
	<i>GJC2</i>	CX47	1	8	1.43 [0.7-2.92]	> 1	0.30	2.42 [1.19-4.96]	1.67E-01	0.59	4.04 [1.89-8.61]	3.02E-03	0.75
	<i>GJD3</i>	CX31.9	4	7	1.92 [1.08-3.41]	2.58E-01	0.48	2.9 [1.63-5.14]	3.02E-03	0.65	3.46 [1.89-6.33]	5.76E-04	0.71
	<i>GJE1</i>	CX23	2	2	238.73 [43.54-1308.91]	2.85E-09	1.00	32.57 [7.93-133.69]	1.47E-05	0.97	10.12 [1.95-52.4]	5.80E-02	0.90

259 The AF in each reference database was compared to the AF in the FMD cohort: the Non-Finnish European for gnomAD (gnomAD NFE), the global population for gnomAD
260 (gnomAD), and the Spanish population for CSVS (CSVS). All the samples are heterozygous for the variants. OR: Odd ratio; CI: Confidence Interval; FDR: p-value corrected
261 by False Discovery Ratio; EF: Etiological Fraction.

262 3.2. Segregation of a rare haplotype in the *GJD3* gene with FMD

263 We found several rare variants in the *GJD3* gene in FMD: two missense variants
264 (NC_000017.11:g.40363058C>G, NC_000017.11:g.40363293G>A) an inframe deletion
265 (NC_000017.11:g.40363099_40363101del), two downstream variants
266 (NC_000017.11:g.40356228C>T, NC_000017.11:g.40356584C>A) and four synonymous variants
267 (NC_000017.11:g.40363294C>G, NC_000017.11:g.40363327G>A, NC_000017.11:g.40363528G>A,
268 NC_000017.11:g.40363579G>T) (Table 2). Interestingly, five of these variants, g.40356228C>T
269 (downstream), g.40363058C>G (missense), g.40363293G>A (missense), g.40363294C>G
270 (synonymous) and g.40363579G>T (synonymous) were shared among five patients with FMD, and
271 were segregated in three families, with a total of ten individuals carrying a haplotype with the five
272 variants. Moreover, this haplotype was found in another eight individuals with non-familial MD that
273 were initially considered as sporadic cases. However, four of them have relatives with incomplete MD
274 phenotype (HL or episodic vestibular symptoms). The variants g.40363293G>A, g.40363294C>G and
275 g.40363579G>T were validated by Sanger sequencing (Figure S2).

276 The LD study showed a strong correlation between the four shared coding variants. The linkage between
277 g.40363293G>A, g.40363294C>G and g.40363579G>T was complete ($R^2 = 1$), and LD between each
278 of them with g.40363058C>G was almost complete ($R^2 = 0.966$) (Figure S3).

279 Since these five variants (g.40356228C>T, g.40363058C>G, g.40363293G>A, g.40363294C>G and
280 g.40363579G>T) seem to form a haplotype (TGAGT), we study the AF in the 1,000 Genomes Project
281 population: 0.0058 for the global population, 0.0159 for the European and 0.0093 for the Iberian in
282 Spain (Table S2). Besides, in the 1,000 Genome Project we found the haplotype CGGCG, present only
283 in one individual in the population of 1,000 Genomes Project, originally from Spain (AF global =
284 0.0002, AF European = 0.001, AF Iberian in Spain = 0.0047). This CGGCG haplotype had the reference
285 allele for all the variants except for the g.40363058C>G missense variant. This genotype has been
286 shown in another three non-familial MD individuals of our cohort (Table 2, Table S2).

287 The constraint of the *GJD3* gene for missense variants - according to gnomAD - is determined by the
288 Z score = 0.76, and the ratio observed/expect = 0.78 [0.64 - 0.95]. The ratio less than 1 and the positive
289 Z score value suggest that the gene is highly conserved, and intolerant to variation.

290 **Table 2.** Variants in *GJD3* connexin gene found in Familial Meniere Disease (FMD) cases.

Variant	Amino acid change	Consequence	CADD score	ACMG classification	Number individuals			AF		
					FMD in GBA	FMD total (families segregate)	SMD	gnomAD NFE	gnomAD	CSVS
NC_000017.11:g.40356228C>T	-	Downstream	5.07	Uncertain significance (PP1,BP4)	5 ^a	10 ^a (3)	8 ^a	2.30E-02	1.53E-02	1.40E-02
NC_000017.11:g.40356584C>A	-	Downstream	7.072	Likely benign (BP4)	2	2	20	1.76E-02	1.27E-02	2.60E-02
NC_000017.11:g.40363058C>G	NP_689343.3:p.(Arg253Pro)	Missense	7.695	Likely benign (PP1,BS1,BS2,BP4)	5 ^a	10 ^a (3)	11 ^b	2.30E-02	1.54E-02	6.00E-03
NC_000017.11:g.40363099_40363101del	NP_689343.3:p.(Pro248del)	Inframe deletion	14.95	Uncertain significance (PM2,BP4)	1	1	0	1.60E-05	1.06E-04	-
NC_000017.11:g.40363293G>A	NP_689343.3:p.(His175Tyr)	Missense	18.58	Likely benign (PP1,BS1,BS2,BP4)	5 ^a	10 ^a (3)	8 ^a	2.30E-02	1.53E-02	1.10E-02
NC_000017.11:g.40363294C>G	NP_689343.3:p.Pro174=	Synonymous	16.66	Likely benign (PP1,BS1,BS2,BP4,BP7)	5 ^a	10 ^a (3)	8 ^a	2.30E-02	1.53E-02	1.10E-02
NC_000017.11:g.40363327G>A	NP_689343.3:p.Ala163=	Synonymous	16.74	Likely benign (PM2,BP4,BP7)	1	1	0	-	7.00E-06	2.53E-04
NC_000017.11:g.40363528G>A	NP_689343.3:p.Ser96=	Synonymous	16.77	Likely benign (BP4,BP7,PM2)	1	1	0	4.18E-04	2.38E-04	-
NC_000017.11:g.40363579G>T	NP_689343.3:p.Leu79=	Synonymous	20.8	Likely benign (PP1,BS1,BS2,BP4,BP7)	5 ^a	10 ^a (3)	8 ^a	2.30E-02	1.54E-02	1.50E-02

291 ^a: Same individuals with the TGAGT haplotype; ^b: Same 8 individuals with the TGAGT haplotype + another 3 individuals with the CGGCG haplotype. CADD: Combined
 292 Annotation Dependent Depletion; ACMG: American College of Medical Genetics and Genomics; FMD: Familial Meniere Disease; GBA: Gene burden analysis;
 293 SMD: Sporadic Meniere Disease; gnomAD: Genome Aggregation Database; NFE: Non-Finnish European; CSVS: Collaborative Spanish Variant Server.

294 3.3. Characterization of individuals carrying *GJD3* variants

295 A detailed clinical characterization of the hearing profile was performed for the 18 individuals with the
296 TGAGT rare haplotype. From the five familial probands, the segregation in three of those families was
297 confirmed (families F1, F2, and F3; pedigrees are not shown to prevent patients' identification, but they
298 are available for reviewers a researcher upon reasonable request); however, it was not possible to obtain
299 blood samples from relatives of two probands (F4 and F5).

300 The proband (III-6) of family 1 (F1) was a woman in the early 50s with definite MD. Her progenitor
301 (II-5) was also diagnosed with definite MD with Tumarkin crisis, both carrying the variants studied.
302 Moreover, a relative of the proband (II-1) was diagnosed with probable MD and he did not have the
303 same variants. His clinical history differs from the other two cases, as his age of onset for MD was in
304 the 70s, relatively older than that of the proband and her progenitor, which was in the 30s and in the 60s,
305 respectively. Moreover, his flat hearing profile does not show a drop in high frequencies (Figure 1).

306 In family 2 (F2) the proband (III-13) was a woman in the early 60s with definite MD. Her progenitor
307 (II-5) also suffered from MD, and four of her five siblings and two relatives have vertigo attacks.
308 Besides, one of her two relatives presented HL, and his descendant (III-7) was also diagnosed with
309 definite MD. They all started with episodic symptoms at a similar age in their 40s. The three cases with
310 MD have the studied variants. Nevertheless, it was not possible to obtain samples for the individuals
311 with incomplete phenotypes.

312 The proband (II-4) of the third family (F3) was a man in the early 70s with definite MD. His progenitor
313 (I-1) was also diagnosed with definite MD, whereas his sibling (II-3) had probable MD based on the
314 audiometry results. In this family, all these three individuals carry the variants of interest, and they have
315 a similar age of onset, in their 40s. Furthermore, none of his children suffer from inner ear disorders,
316 but his granddaughter (IV-1) has presented high-frequency HL since her birth. Neither IV-1 nor her
317 parents (III-3 and III-4) were carriers of the studied variants.

318 The case in F4 was a woman in the 70s with definite MD, bilateral HL (Figure S4), with an onset at her
319 30s and a history of migraine and autoimmune diseases. The F5 case was a woman with definite MD,
320 with bilateral HL, and her age at HL onset was in her 20s.

321 In addition, four (S1, S2, S3, and S4) of the eight SMD cases with the studied variants have first-degree
322 relatives with vertigo and SNHL or only episodic vertigo. Interestingly, the three SMD cases (S9, S10
323 and S11) with the CGGCG haplotype did not report relatives with HL or vestibular disorders (Figure
324 S4).





Figure 1. Air conduction audiogram of families 1-3. dB: decibels, kHz: kilohertz.

327 3.4. Protein modeling

328 The monomeric structure of the Gap junction delta-3 protein (Q8N144) - called GJD3 and CX31.9 -
329 encoded by the *GJD3* gene, was predicted using AlphaFold2. Furthermore, both the hexameric
330 connexon in a closed conformation, with a C6 symmetry, and the structure of the homotypic GJD3
331 channel, formed by two identical connexons along a two-fold crystallographic symmetry axis, were
332 modeled (Figure 2). Based on the geometrical validation results, reliable models have been built
333 compared to structures solved by experimental methods at the geometrical level (Table S3). These
334 models were used to predict the impact of the variants found on the stability of the monomer, connexon
335 and gap junction models.

336 The NP_689343.3:p.(His175Tyr), NP_689343.3:p.(Pro248del), NP_689343.3:p.(Arg253Pro) variants
337 were predicted in-silico as neutral ($-0.5 < \Delta\Delta G_{\text{pred}} < 0.5$) according to the predicted change in global
338 GJD3 monomer stability for the majority of methods used (Table S4). The effect on protein stability of
339 the NP_689343.3:p.(His175Tyr) and NP_689343.3:p.(Arg253Pro) variants, found together in the same
340 patients, have also been predicted to be neutral.

341 In the homomeric connexon and the homotypic gap junction models, the NP_689343.3:p.(His175Tyr)
342 variant was predicted to have a stabilizing effect on the structure of the complex (Table S5).
343 Nevertheless, based on the model and the interaction between the two connexons, the replacement of
344 the histidine by tyrosine would affect the formation of the channel, since the electrostatic interaction
345 between histidine 175 and aspartic 178 would be lost and replaced by the larger and uncharged amino
346 acid tyrosine. Therefore, it could potentially alter the interaction between both connexons (Figure 2).




347
348 **Figure 2.** Model of the human CX31.9 gap junction formed by two homomeric connexons; and
349 change produced by the NP_689343.3:p.(His175Tyr) variant comparing the wild-type protein with the
350 mutated.

351 3.5. Cx30.2 localization in mouse inner ear

352 Immunofluorescence was used to examine the localization of the Gap junction delta-3 protein (Gjd3,
353 Q91YD1) - also known as Cx30.2 - encoded by *Gjd3*, which is an orthologue of the *GJD3* human gene.
354 Firstly, immunofluorescence labeling of Cx30.2 in P90 adult mouse inner ear showed dispersed
355 punctiform labeling in the cochlea, localized at the spiral limbus, TM, nerve fibers, and organ of Corti;
356 especially below the basal pole of inner hair cells (Figure 3A-B). In addition, immunofluorescence
357 labeling was observed at the macula and crista epithelium (Figure S5). Significant differences were
358 found between the *Gjd3* expression in mice cochleae of animals that were one and six months ($p =$
359 0.011); the lower value of ΔCt at 1-month-old showed a higher expression than in 6-month-old mice
360 ($\text{FC} \pm \text{SEM} = 0.610 \pm 0.057$). Although expression was higher in 1-month-old mice than in 12-month-
361 old ($\text{FC} \pm \text{SEM} = 0.747 \pm 0.111$), that difference was not statistically significant ($p = 0.073$, Figure 3C).


362 Therefore, cochleae from younger mice were studied to analyze the localization of Cx30.2 during
363 development. In P30 adult mouse cochleae, expression was predominantly observed in the TM but also
364 in the supporting cells of the organ of Corti and the basilar membrane (Figure 3D-F). In the P3 young
365 mouse cochleae, the labeling of the TM was the most intense; furthermore, Cx30.2 was expressed in the
366 hair and supporting cells from the organ of Corti, stria vascularis, basilar membrane, and cartilage
367 (Figure 3G-I).



368
 369 **Figure 3.** Expression of Cx30.2 at the cochlea of postnatal day 90 (P90) adult (A-B), postnatal day 30
 370 (P30) adult (D-F), and postnatal day 3 (P3) young (G-I) mouse inner ear sections, and expression in
 371 mouse development (C). A-B: Gjd3 appears in the cochlea in a very disperse punctiform
 372 immunofluorescence labeling at spiral limbus (SL), nerve fibers region (NF), tectorial membrane
 373 (TM) and the organ of Corti; with more dense patches at TM or below the inner hair cells (IHC). C:
 374 Gene expression (ΔCt) of *Gjd3* in 1, 6 and 12-month-old mouse cochleae (in each age group, there are
 375 four pools, each consisting of three cochleae). Student's t-test was used to calculate the *p* value in each
 376 comparison. D-F: The punctiform immunofluorescence labeling of Gjd3 in the P30 cochlea was
 377 observed especially at the TM, and also at the basilar membrane (BM) and supporting cells (SC). G-I:
 378 The immunofluorescence revealed strong expression of Gjd3 in the P3 cochlea at the TM, and also in
 379 a punctiform labeling at the cartilage, stria vascularis (SV), BM, IHC, outer hair cells (OHC), and SC.
 380 The Connexins 30.2 (Cx30.2) - encoded by the mouse *Gjd3* gene - are stained using the rabbit
 381 polyclonal anti-Connexin 30.2, LifeTechnologies, # 40-7400 (green), and the nuclei are stained using
 382 DAPI (blue). Scale bar 50 μm (A, B, E and H), 100 μm (D and G), and 20 μm (F and I).

383 3.6. Functional characterization of human CX31.9 in *Xenopus laevis* 384 oocytes

385 To examine the functional properties of human CX31.9 hemichannels, we expressed the CX31.9 in
386 *Xenopus laevis* oocytes, and measured currents in response to a wide range of voltage steps (+80 to -
387 100 mV) from a holding potential of -40 mV. Consistent with the functional expression of hemichannels,
388 *Xenopus* oocytes injected with CX31.9 WT RNA showed significantly larger currents at +80 mV and -
389 100 mV compared to uninjected oocytes ($p < 0.0001$, $n = 33$ for WT, $n = 28$ for uninjected; Figure 4B).
390 The NP_689343.3:p.(His175Tyr) variant showed WT-level current amplitudes at +80 mV (WT: $856 \pm$
391 $275 \mu\text{A}$, $n = 33$; H175Y: $845 \pm 290 \mu\text{A}$, $n = 28$; $p = 0.88$) and -100 mV (WT: $-382 \pm 112 \mu\text{A}$, $n = 33$;
392 H175Y: $-366 \pm 99 \mu\text{A}$, $n = 28$; $p = 0.79$). The NP_689343.3:p.(Arg253Pro) variant, on the other hand,
393 showed a slight increase in current amplitudes compared to WT at +80 mV (R253P: $1007 \pm 406 \mu\text{A}$, n
394 $= 40$, $p = 0.065$) and at -100 mV (R253P: $-453 \pm 141 \mu\text{A}$, $n = 40$, $p = 0.0092$).



395
396 **Figure 4.** Functional expression of human CX31.9 hemichannels in *Xenopus laevis* oocytes. A:
397 Representative current traces of *Xenopus* oocytes that are untreated (not injected with RNA) and
398 expressing CX31.9 wild-type, NP_689343.3:p.(His175Tyr) and NP_689343.3:p.(Arg253Pro)
399 hemichannels in response to a voltage-step protocol from +80 mV to -100 mV (holding potential = -40
400 mV). B: Current amplitudes elicited at +80 mV and -100 mV. Floating bars show the third quartile,
401 median (middle line) and first quartile values. WT: wild-type; H175Y: NP_689343.3:p.(His175Tyr);
402 R253P: NP_689343.3:p.(Arg253Pro); ns: $p < 0.05$; **: $p \leq 0.01$; ****: $p \leq 0.0001$; Student's t-test.

403 4. Discussion

404 The main finding in this work is the burden of rare variants in the human *GJD3* connexin gene in FMD.
405 By manual inspection and segregation analyses of these variants, our study has identified a rare TGAGT
406 haplotype in the gene *GJD3* that segregates the complete phenotype in multiple unrelated families with
407 MD and supports an association of *GJD3* with FMD. Furthermore, immunofluorescence experiments
408 reveal the presence of Gjd3 protein in mice cochleae and vestibules; and, unexpectedly, Gjd3 has been
409 localized for the first time in the TM.

410 Two missense, two synonymous and one downstream variants segregate with dominant pattern in three
411 different families with some individuals affected by MD; in addition, in another two familial cases and
412 eight sporadic individuals, having four of them first-degree relatives with incomplete phenotype. The
413 18 MD cases shared the same haplotype TGAGT for the variants: NC_000017.11:g.40356228C>T,
414 NC_000017.11:g.40363058C>G, NC_000017.11:g.40363293G>A, NC_000017.11:g.40363294C>G
415 and NC_000017.11:g.40363579G>T; whose frequency in the Iberian population in Spain is 0.0093. The
416 low frequency of the haplotype and the segregation in non-related families leads to the association with
417 the disease. The most interesting variant is NC_000017.11:g.40363293G>A,
418 NP_689343.3:p.(His175Tyr) at the protein level, which produces an amino acid change from a
419 positively charged histidine to a bulky and hydrophobic tyrosine in the extracellular extreme of the
420 connexon. This replacement would produce the loss of the electrostatic interactions that occur between
421 histidine 175 and aspartic 178 in each of the six connexins conforming the homomeric connexon,
422 altering the correct arrangement between two connexons to form the channel. Although the
423 electrophysiological characterization of WT and the mutated NP_689343.3:p.(His175Tyr) CX31.9
424 hemichannels in *Xenopus laevis* oocytes demonstrated no differences in the current amplitudes (Figure
425 4B); the amino acid change could modify the interaction between both connexons, leading to decreased
426 formation of homotypic gap junction channels. Likewise, Schadzek et al.⁵⁹ demonstrated that a missense
427 variant in an extracellular loop (as in our case) of CX46 - encoded by *GJA3* - is related to an autosomal
428 dominant zonular pulverulent cataract. In this case, they demonstrated that the mutated connexin
429 affected the co-expressed wild type (wt) connexin to achieve a dominant inheritance. The heterodimer
430 mutated-wt made less gap junction plaques than the homodimer wt-wt, and the homodimer mutated-
431 mutated formed almost none.

432 In addition, it has been demonstrated that Gjd3 can form heterotypic channels with other three connexins
433 in mice heart cells^{60,61}. We suspect that, in the same way, Gjd3 could form heteromeric connexons and
434 heterotypic channels in the cochlea with the other connexins expressed, as it has been demonstrated with
435 Cx26, Cx30 and Cx31 - also named Gjb2, Gjb6 and Gjb3, respectively. Heteromeric Gjb2/Gjb6
436 channels have been found connecting cochlear supporting cells, and the Gjb2 and Gjb3 also form
437 heteromeric Gjb2/Gjb3 connexons and homomeric/heterotypic Gjb2/Gjb3 gap junctions⁶²⁻⁶⁴. The

438 correct arrangement of a heterotypic connexon also would be affected by the
439 NC_000017.11:g.40363293G>A variant. Nevertheless, it cannot be asserted that the expression of
440 human GJD3 is identical to that of mouse Gjd3 in the cochlea, as observed in the heart ⁶⁵.

441 It is currently not possible to model the mutant hemichannel NP_689343.3:p.(Arg253Pro) as the residue
442 is located in the highly flexible cytoplasmic region, which also remains unresolved in other connexin
443 structural studies ⁶⁶. Therefore, we used an electrophysiological assay to assess potential functional
444 impact of this variant. Electrophysiological characterization of the mutated
445 NP_689343.3:p.(Arg253Pro) CX31.9 hemichannel in *Xenopus laevis* oocytes showed that at
446 hyperpolarized potentials, the current amplitudes were significantly larger than the WT hemichannels
447 (Figure 4B). As the increase in current amplitudes was small and the functional significance of the
448 cytoplasmic region of connexins is currently poorly understood, we refrain from drawing any conclusion
449 about this finding. Future studies investigating the effect of this variant in gap junction channels will
450 help clarify the pathogenicity of this variant.

451 Hearing relies on the displacements of the stereocilia of hair cells provoked by sound. The membrane
452 depolarization entails fluxes of Ca²⁺ and K⁺ into the cell, leading to the excitation of the auditory nerve
453 ^{67,68}. As evidenced in prior research, inner ear connexins are essential in the Ca²⁺ signaling ⁶⁹. Besides,
454 there are Ca²⁺-rich filamentous structures in the TM that are involved in the connection of the TM and
455 the hair cell stereocilia, which assure the mechanical stimulation and the obtention of Ca²⁺ by the hair
456 cells ⁶⁸. Our IF data confirm the expression of Gjd3 in the mouse TM and we speculate that GJD3 could
457 be related to the function of those filamentous ducts. Moreover, regarding the cycling transport of K⁺,
458 the K⁺ flows through the hair cells from the endolymph to the perilymph ⁷⁰. The TM is sealed, therefore
459 to arrive at the hair cells from the endolymph, the K⁺ must cross the TM ⁷¹. We hypothesize that GJD3
460 may contribute to maintaining the local ionic microenvironment driving K⁺ fluxes to the tip of
461 stereocilia. When the K⁺ arrives to the hair cells, it reaches to the perilymph through scala tympani, then
462 to the spiral ligament, and arrives to the stria vascularis, where it is returned to the endolymph. It has
463 been studied that the GJB2, GJB3 and GJB6 connexins are crucial in this transport ^{4,63,70}. Because of
464 that, we propose that GJD3, which we found expressed some of these cells and structures, should be
465 involved in the K⁺ cycle.

466 Furthermore, the connexins Gjb2, Gjb6 and Gjal have been found in mammalian vestibular system ⁷².
467 Our IF data in the vestibular organs confirm a labeling of Gjd3 below the macular epithelium; however,
468 further studies with higher resolution are needed to confirm these observations.

469 By exome sequencing and familial analysis different genes have been found associated with MD.
470 Particularly, an enrichment of rare missense variants in 15 unrelated MD families, with 6 of them
471 showing compound heterozygous recessive inheritance in *OTOG*, and rare missense variants and two
472 short deletions were identified in four different MD families in *TECTA* genes, respectively; both genes

473 encode non-collagenous proteins of the TM ^{13,15}. Moreover, the other nine unrelated families presented
474 rare variants in the *MYO7A* gene, expressed in the stereocilia of the hair cells in the sensory epithelia ¹⁴.
475 Taken together, these studies and the findings in *GJD3*, suggest that the proteins involved in the
476 architecture of the stereocilia links and the attachment of the stereocilia tips to the TM could be involved
477 in the pathophysiology of MD.

478 In the present work, the type of inheritance observed in the TGAGT rare haplotype in *GJD3* in three
479 MD families was autosomal dominant. Three different inheritance modes have been reported in FMD:
480 autosomal dominant, autosomal recessive and digenic inheritance. These outcomes describe a complex
481 inheritance, that coupled with specific environmental factors, could lead to variation of phenotype,
482 including the HL profile, and age of onset, even in the same family ⁷³. Moreover, epigenetic
483 modifications could probably shape clinical manifestation. By whole-genome bisulfite sequencing
484 (WGBS), CpGs in *ADGRV1* (MIM: 602851), *CDH23* (MIM: 605516) and *PCDH15* (MIM: 605514)
485 were determined as differentially methylated when comparing MD against healthy controls. Those genes
486 encode for stereocilia link proteins, which are involved in attaching the hair cells to the TM ¹¹.

487 Furthermore, in the 3 non-familial cases with the CGGCG haplotype (displaying the reference alleles
488 except for the NC_000017.11:g.40363058C>G missense variant), the variant alone would not explain
489 the phenotype. However, it is very interesting for future work opening the possibility to study the
490 complete genome to identify regulatory variants in *GJD3*, as in the promoters or in the 5' or 3'
491 untranslated regions (UTRs); and/or study in combination the genetics with epigenetics in sporadic
492 cases.

493 Conclusions

- 494 1. A rare haplotype in the gene *GJD3* segregates in unrelated families with Meniere Disease.
- 495 2. Cx30.2 is localized in mouse cochlea, including the tectorial membrane, and vestibule.
- 496 3. The variants found may involve the interactions between two connexons leading to dysfunction
497 in the channels.
- 498 4. In line with previous findings, our results support that the proteins of the tectorial membrane
499 and the stereocilia link could be involved in the molecular pathophysiology of familial MD.

500 Limitations

- 501 1. The lack of clinical record and DNA samples of some participants, made it difficult to segregate
502 the haplotype in some individuals.
- 503 2. This study was limited to coding sequences, and whole genome sequencing data will be needed
504 to study non-coding regions and its relation with the disease.
- 505 3. Additional functional studies will be necessary to understand the function and the consequences
506 of the missense variants in the human CX31.9 protein in the inner ear.

507 **Acknowledgments**

508 This work is part of Alba Escalera-Balsera's doctoral thesis. Alba Escalera-Balsera is enrolled in the
509 Biomedicine Ph.D. program at the University of Granada, Spain. We would also like to recognize Dr
510 Lidia Frejo for suggestions with immunofluorescence analysis.

511 **Author contributions**

512 Conceptualization, A.E.-B. and J.A.L.-E.; Methodology, A.E.-B., P.R.-B., A.M.P.-P., C.H.C., L.R.-
513 dlR., J.C. and E.D.; Software, A.E.-B., A.M.P.-P. and A.G.-M.; Formal Analysis, A.E.-B.; Investigation,
514 A.E.-B., S.M.-C., C.H.C. and A.G.-M.; Resources, J.C.A.-D., A.S.-V., I.V.-N., A.J.S. and J.A.L.-E.;
515 Data Curation, A.E.-B.; Writing – Original Draft Preparation, A.E.-B. and J.A.L.-E.; Writing – Review
516 & Editing, P.R.-B., A.M.P.-P., S.M.-C., C.H.C., L.R.-dlR., J.C., E.D., J.C.A.-D., A.S.-V., I.V.-N.,
517 A.J.S., A.G.-M. and J.A.L.-E.; Visualization, A.E.-B., P.R.-B. and A.M.P.-P.; Supervision, I.V.-N.,
518 A.J.S., A.G.-M. and J.A.L.-E.; Project Administration, J.A.L.-E.; Funding Acquisition, J.A.L.-E..

519 **Funding**

520 JALE has received funds to support research on genetics in Meniere's disease by The University of
521 Sydney (K7013_B3413 Grant), Asociacion Sindrome de Meniere España (ASMES), Meniere's Society,
522 UK, and the European Union's Horizon 2020 Research and Innovation Programme, Grant Agreement
523 Number 848261. AGM has received funds from the Andalusian Health Department (Grant PI-0266-
524 2021) and by CuresWithinReach and the Knight Family. JALE and AGM have received funds from the
525 Andalusian Government (CECEU 2020, grant code: DOC_01677). IVN and SMC have received funds
526 from PID2020-115274RB-I00 MCIN/AEI/10.13039/501100011033 and COST Action CA20113
527 PROTEOCURE. AEB and PRB are funded by the European Union's Horizon 2020 Research and
528 Innovation Programme, Grant Agreement Number 848261. AMPP is supported by a predoctoral grant
529 from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities of
530 Junta de Andalucía (Grant number PREDOC2021/00343). The computations and data handling were
531 enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at
532 SNIC/UPPMAX partially funded by the Swedish Research Council through grant agreement no. 2018-
533 05973.

534 **Institutional review board**

535 The study was conducted according to the guidelines of the Declaration of Helsinki and approved by
536 the Granada Ethical Review Board for Clinical Research under the protocol number 1805-N-20; the
537 Governmental Ethics Commission for Animal Welfare in Berlin under the approval number T 0235/18;
538 and by the Dirección General de Agricultura, Ganadería y Alimentación in Comunidad de Madrid under
539 the approval number PROEX 325.4/21.

540 **Informed consent**

541 Written informed consent has been obtained from the patient(s) to publish this paper.

542 **Data availability**

543 Anonymized genetic raw dataset and family pedigrees used in this study are available from the
544 corresponding author upon reasonable request.

545 **Conflict of interest**

546 The authors declare no conflict of interest.

547 References

- 548 1. Totland MZ, Rasmussen NL, Knudsen LM, Leithe E. Regulation of gap junction intercellular
549 communication by connexin ubiquitination: physiological and pathophysiological implications.
550 *Cell Mol Life Sci.* 2020;77(4):573-591. doi:10.1007/s00018-019-03285-0
- 551 2. Mammano F. Inner Ear Connexin Channels: Roles in Development and Maintenance of Cochlear
552 Function. *Cold Spring Harb Perspect Med.* 2019;9(7):a033233. doi:10.1101/cshperspect.a033233
- 553 3. Srinivas M, Verselis VK, White TW. Human diseases associated with connexin mutations.
554 *Biochim Biophys Acta BBA - Biomembr.* 2018;1860(1):192-201.
555 doi:10.1016/j.bbamem.2017.04.024
- 556 4. Hibino H, Kurachi Y. Molecular and Physiological Bases of the K⁺ Circulation in the Mammalian
557 Inner Ear. *Physiology.* 2006;21(5):336-345. doi:10.1152/physiol.00023.2006
- 558 5. Chen P, Wu W, Zhang J, et al. Pathological mechanisms of connexin26-related hearing loss:
559 Potassium recycling, ATP-calcium signaling, or energy supply? *Front Mol Neurosci.*
560 2022;15:976388. doi:10.3389/fnmol.2022.976388
- 561 6. Sellon JB, Ghaffari R, Freeman DM. The Tectorial Membrane: Mechanical Properties and
562 Functions. *Cold Spring Harb Perspect Med.* 2019;9(10):a033514.
563 doi:10.1101/cshperspect.a033514
- 564 7. Richardson G, Lukashkin A, Russell I. The tectorial membrane: One slice of a complex cochlear
565 sandwich. *Curr Opin Otolaryngol Head Neck Surg.* 2008;16(5):458-464.
566 doi:10.1097/MOO.0b013e32830e20c4
- 567 8. Frejo L, Soto-Varela A, Santos-Perez S, et al. Clinical Subgroups in Bilateral Meniere Disease.
568 *Front Neurol.* 2016;7:182. doi:10.3389/fneur.2016.00182
- 569 9. Frejo L, Martin-Sanz E, Teggi R, et al. Extended phenotype and clinical subgroups in unilateral
570 Meniere disease: A cross-sectional study with cluster analysis. *Clin Otolaryngol Off J ENT-UK*
571 *Off J Neth Soc Oto-Rhino-Laryngol Cervico-Facial Surg.* 2017;42(6):1172-1180.
572 doi:10.1111/coa.12844
- 573 10. Frejo L, Gallego-Martinez A, Requena T, et al. Proinflammatory cytokines and response to molds
574 in mononuclear cells of patients with Meniere disease. *Sci Rep.* 2018;8(1):5974.
575 doi:10.1038/s41598-018-23911-4
- 576 11. Flook M, Escalera-Balsera A, Gallego-Martinez A, et al. DNA Methylation Signature in
577 Mononuclear Cells and Proinflammatory Cytokines May Define Molecular Subtypes in Sporadic
578 Meniere Disease. *Biomedicines.* 2021;9(11):1530. doi:10.3390/biomedicines9111530
- 579 12. Escalera-Balsera A, Roman-Naranjo P, Lopez-Escamez JA. Systematic Review of Sequencing
580 Studies and Gene Expression Profiling in Familial Meniere Disease. *Genes.* 2020;11(12):1414.
581 doi:10.3390/genes11121414
- 582 13. Roman-Naranjo P, Gallego-Martinez A, Soto-Varela A, et al. Burden of Rare Variants in the
583 OTOG Gene in Familial Meniere's Disease. *Ear Hear.* 2020;41(6):1598-1605.
584 doi:10.1097/AUD.0000000000000878
- 585 14. Roman-Naranjo P, Moleon MDC, Aran I, et al. Rare coding variants involving MYO7A and other
586 genes encoding stereocilia link proteins in familial meniere disease. *Hear Res.* 2021;409:108329.
587 doi:10.1016/j.heares.2021.108329
- 588 15. Roman-Naranjo P, Parra-Perez AM, Escalera-Balsera A, et al. Defective α -tectorin may involve
589 tectorial membrane in familial Meniere disease. *Clin Transl Med.* 2022;12(6):e829.
590 doi:10.1002/ctm2.829
- 591 16. Gallego-Martinez A, Requena T, Roman-Naranjo P, Lopez-Escamez JA. Excess of Rare Missense
592 Variants in Hearing Loss Genes in Sporadic Meniere Disease. *Front Genet.* 2019;10:76.
593 doi:10.3389/fgene.2019.00076
- 594 17. Lopez-Escamez JA, Carey J, Chung WH, et al. Diagnostic criteria for Menière's disease. *J Vestib*
595 *Res Equilib Orientat.* 2015;25(1):1-7. doi:10.3233/VES-150549
- 596 18. Wickham H, Girlich M. tidy: Tidy Messy Data. Published online 2022. [https://CRAN.R-](https://CRAN.R-project.org/package=tidy)
597 [project.org/package=tidy](https://CRAN.R-project.org/package=tidy)
- 598 19. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Published online 2016.
599 <https://ggplot2.tidyverse.org>

- 600 20. Wickham H, François R, Henry L, Müller K. dplyr: A Grammar of Data Manipulation. Published
601 online 2022. <https://CRAN.R-project.org/package=dplyr>
- 602 21. Kassambara A. ggpubr: “ggplot2” Based Publication Ready Plots. Published online 2020.
603 <https://CRAN.R-project.org/package=ggpubr>
- 604 22. Wickham H, Seidel D. scales: Scale Functions for Visualization. Published online 2022.
605 <https://CRAN.R-project.org/package=scales>
- 606 23. World Medical Association. World Medical Association Declaration of Helsinki: ethical
607 principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191-2194.
608 doi:10.1001/jama.2013.281053
- 609 24. Szczepek AJ, Frejo L, Vona B, et al. Recommendations on Collecting and Storing Samples for
610 Genetic Studies in Hearing and Tinnitus Research. *Ear Hear*. 2019;40(2):219-226.
611 doi:10.1097/AUD.0000000000000614
- 612 25. Garcia M, Juhos S, Larsson M, et al. Sarek: A portable workflow for whole-genome sequencing
613 analysis of germline and somatic variants. *F1000Research*. 2020;9:63.
614 doi:10.12688/f1000research.16665.2
- 615 26. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: A MapReduce framework
616 for analyzing next-generation DNA sequencing data. *Genome Res*. 2010;20(9):1297-1303.
617 doi:10.1101/gr.107524.110
- 618 27. Poplin R, Ruano-Rubio V, DePristo MA, et al. Scaling accurate genetic variant discovery to tens
619 of thousands of samples. Published online July 24, 2018:201178. doi:10.1101/201178
- 620 28. Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools. *GigaScience*.
621 2021;10(2):giab008. doi:10.1093/gigascience/giab008
- 622 29. Tiao G, Goodrich J. gnomAD v3.1 New Content, Methods, Annotations, and Data Availability.
623 gnomAD v3.1 New Content, Methods, Annotations, and Data Availability. Published 2020.
624 Accessed March 16, 2023. [gnomad.broadinstitute.org/news/2020-10-gnomad-v3-1-new-content-](https://gnomad.broadinstitute.org/news/2020-10-gnomad-v3-1-new-content-methods-annotations-and-data-availability/)
625 [methods-annotations-and-data-availability/](https://gnomad.broadinstitute.org/news/2020-10-gnomad-v3-1-new-content-methods-annotations-and-data-availability/)
- 626 30. GeneCards - Human Genes | Gene Database | Gene Search. Accessed April 12, 2022.
627 <https://www.genecards.org/>
- 628 31. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from
629 variation in 141,456 humans. *Nature*. 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7
- 630 32. Peña-Chilet M, Roldán G, Perez-Florido J, et al. CSVS, a crowdsourcing database of the Spanish
631 population genetic variability. *Nucleic Acids Res*. 2021;49(D1):D1130-D1137.
632 doi:10.1093/nar/gkaa794
- 633 33. Walsh R, Mazzarotto F, Whiffin N, et al. Quantitative approaches to variant classification increase
634 the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic
635 cardiomyopathy. *Genome Med*. 2019;11:5. doi:10.1186/s13073-019-0616-z
- 636 34. Cai T, Jen HI, Kang H, Klisch TJ, Zoghbi HY, Groves AK. Characterization of the transcriptome
637 of nascent hair cells and identification of direct targets of the Atoh1 transcription factor. *J*
638 *Neurosci Off J Soc Neurosci*. 2015;35(14):5870-5883. doi:10.1523/JNEUROSCI.5083-14.2015
- 639 35. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for
640 estimating the relative pathogenicity of human genetic variants. *Nat Genet*. 2014;46(3):310-315.
641 doi:10.1038/ng.2892
- 642 36. Shearer AE, Eppsteiner RW, Booth KT, et al. Utilizing ethnic-specific differences in minor allele
643 frequency to recategorize reported pathogenic deafness variants. *Am J Hum Genet*.
644 2014;95(4):445-453. doi:10.1016/j.ajhg.2014.09.001
- 645 37. Myers TA, Chanock SJ, Machiela MJ. LDlinkR: An R Package for Rapidly Calculating Linkage
646 Disequilibrium Statistics in Diverse Populations. *Front Genet*. 2020;11:157.
647 doi:10.3389/fgene.2020.00157
- 648 38. Shin JH, Blay S, McNeney B, Graham J. LDheatmap: An R Function for Graphical Display of
649 Pairwise Linkage Disequilibria Between Single Nucleotide Polymorphisms. *J Stat Softw*.
650 2006;16:1-9. doi:10.18637/jss.v016.c03
- 651 39. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold.
652 *Nature*. 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2
- 653 40. Yan Y, Tao H, He J, Huang SY. The HDock server for integrated protein–protein docking. *Nat*
654 *Protoc*. 2020;15(5):1829-1852. doi:10.1038/s41596-020-0312-x

- 655 41. Williams CJ, Headd JJ, Moriarty NW, et al. MolProbity: More and better reference data for
656 improved all-atom structure validation: PROTEIN SCIENCE.ORG. *Protein Sci.* 2018;27(1):293-
657 315. doi:10.1002/pro.3330
- 658 42. Eisenberg D, Lüthy R, Bowie JU. VERIFY3D: Assessment of protein models with three-
659 dimensional profiles. In: *Methods in Enzymology*. Vol 277. Elsevier; 1997:396-404.
660 doi:10.1016/S0076-6879(97)77022-8
- 661 43. Colovos C, Yeates TO. Verification of protein structures: Patterns of nonbonded atomic
662 interactions. *Protein Sci.* 1993;2(9):1511-1519. doi:10.1002/pro.5560020916
- 663 44. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in
664 three-dimensional structures of proteins. *Nucleic Acids Res.* 2007;35(Web Server):W407-W410.
665 doi:10.1093/nar/gkm290
- 666 45. Studer G, Rempfer C, Waterhouse AM, Gumienny R, Haas J, Schwede T. QMEANDisCo—
667 distance constraints applied on model quality estimation. *Bioinformatics.* 2020;36(8):2647-2647.
668 doi:10.1093/bioinformatics/btaa058
- 669 46. Fiser A, Šali A. Modeller: Generation and Refinement of Homology-Based Protein Structure
670 Models. In: *Methods in Enzymology*. Vol 374. Elsevier; 2003:461-491. doi:10.1016/S0076-
671 6879(03)74020-8
- 672 47. Frappier V, Chartier M, Najmanovich RJ. ENCoM server: exploring protein conformational space
673 and the effect of mutations on protein function and stability. *Nucleic Acids Res.*
674 2015;43(W1):W395-W400. doi:10.1093/nar/gkv343
- 675 48. Rodrigues CHM, Pires DEV, Ascher DB. DynaMut2: Assessing changes in stability and
676 flexibility upon single and multiple point missense mutations. *Protein Sci Publ Protein Soc.*
677 2021;30(1):60-69. doi:10.1002/pro.3942
- 678 49. Capriotti E, Fariselli P, Casadio R. I-Mutant2.0: predicting stability changes upon mutation from
679 the protein sequence or structure. *Nucleic Acids Res.* 2005;33(Web Server issue):W306-W310.
680 doi:10.1093/nar/gki375
- 681 50. Pires DEV, Ascher DB, Blundell TL. mCSM: predicting the effects of mutations in proteins using
682 graph-based signatures. *Bioinforma Oxf Engl.* 2014;30(3):335-342.
683 doi:10.1093/bioinformatics/btt691
- 684 51. Pires DEV, Rodrigues CHM, Ascher DB. mCSM-membrane: predicting the effects of mutations
685 on transmembrane proteins. *Nucleic Acids Res.* 2020;48(W1):W147-W153.
686 doi:10.1093/nar/gkaa416
- 687 52. Rodrigues CHM, Pires DEV, Ascher DB. mmCSM-PPI: predicting the effects of multiple point
688 mutations on protein–protein interactions. *Nucleic Acids Res.* 2021;49(W1):W417-W424.
689 doi:10.1093/nar/gkab273
- 690 53. Worth CL, Preissner R, Blundell TL. SDM—a server for predicting effects of mutations on
691 protein stability and malfunction. *Nucleic Acids Res.* 2011;39(Web Server issue):W215-W222.
692 doi:10.1093/nar/gkr363
- 693 54. Chen Y, Lu H, Zhang N, Zhu Z, Wang S, Li M. PremPS: Predicting the impact of missense
694 mutations on protein stability. *PLoS Comput Biol.* 2020;16(12):e1008543.
695 doi:10.1371/journal.pcbi.1008543
- 696 55. Pancotti C, Benevenuta S, Birolo G, et al. Predicting protein stability changes upon single-point
697 mutation: a thorough comparison of the available tools on a new dataset. *Brief Bioinform.*
698 2022;23(2):bbab555. doi:10.1093/bib/bbab555
- 699 56. Celaya AM, Sánchez-Pérez I, Bermúdez-Muñoz JM, et al. Deficit of mitogen-activated protein
700 kinase phosphatase 1 (DUSP1) accelerates progressive hearing loss. *eLife.* 2019;8:e39159.
701 doi:10.7554/eLife.39159
- 702 57. Bermúdez-Muñoz JM, Celaya AM, Hijazo-Pechero S, Wang J, Serrano M, Varela-Nieto I. G6PD
703 overexpression protects from oxidative stress and age-related hearing loss. *Aging Cell.*
704 2020;19(12):e13275. doi:10.1111/ace1.13275
- 705 58. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat*
706 *Methods.* 2012;9(7):671-675. doi:10.1038/nmeth.2089
- 707 59. Schadzek P, Stahl Y, Preller M, Ngezahayo A. Analysis of the dominant mutation N188T of
708 human connexin46 (hCx46) using concatenation and molecular dynamics simulation. *FEBS Open*
709 *Bio.* 2019;9(5):840-850. doi:10.1002/2211-5463.12624

- 710 60. Gemel J, Lin X, Collins R, Veenstra RD, Beyer EC. Cx30.2 can form heteromeric gap junction
711 channels with other cardiac connexins. *Biochem Biophys Res Commun*. 2008;369(2):388-394.
712 doi:10.1016/j.bbrc.2008.02.040
- 713 61. Rackauskas M, Verselis VK, Bukauskas FF. Permeability of homotypic and heterotypic gap
714 junction channels formed of cardiac connexins mCx30.2, Cx40, Cx43, and Cx45. *Am J Physiol*
715 *Heart Circ Physiol*. 2007;293(3):H1729-H1736. doi:10.1152/ajpheart.00234.2007
- 716 62. Defourny J, Thiry M. Recent insights into gap junction biogenesis in the cochlea. *Dev Dyn Off*
717 *Publ Am Assoc Anat*. 2023;252(2):239-246. doi:10.1002/dvdy.538
- 718 63. Defourny J, Thelen N, Thiry M. Cochlear connexin 30 homomeric and heteromeric channels
719 exhibit distinct assembly mechanisms. *Mech Dev*. 2019;155:8-14. doi:10.1016/j.mod.2018.10.001
- 720 64. Liu XZ, Yuan Y, Yan D, et al. Digenic inheritance of non-syndromic deafness caused by
721 mutations at the gap junction proteins Cx26 and Cx31. *Hum Genet*. 2009;125(1):53-62.
722 doi:10.1007/s00439-008-0602-9
- 723 65. Kreuzberg MM, Liebermann M, Segschneider S, et al. Human connexin31.9, unlike its
724 orthologous protein connexin30.2 in the mouse, is not detectable in the human cardiac conduction
725 system. *J Mol Cell Cardiol*. 2009;46(4):553-559. doi:10.1016/j.yjmcc.2008.12.007
- 726 66. Myers JB, Haddad BG, O'Neill SE, et al. Structure of native lens connexin 46/50 intercellular
727 channels by cryo-EM. *Nature*. 2018;564(7736):372-377. doi:10.1038/s41586-018-0786-7
- 728 67. LeMasurier M, Gillespie PG. Hair-cell mechanotransduction and cochlear amplification. *Neuron*.
729 2005;48(3):403-415. doi:10.1016/j.neuron.2005.10.017
- 730 68. Hakizimana P, Fridberger A. Inner hair cell stereocilia are embedded in the tectorial membrane.
731 *Nat Commun*. 2021;12:2604. doi:10.1038/s41467-021-22870-1
- 732 69. Anselmi F, Hernandez VH, Crispino G, et al. ATP release through connexin hemichannels and
733 gap junction transfer of second messengers propagate Ca²⁺ signals across the inner ear. *Proc Natl*
734 *Acad Sci U S A*. 2008;105(48):18770-18775. doi:10.1073/pnas.0800793105
- 735 70. Wangemann P. K⁺ cycling and the endocochlear potential. *Hear Res*. 2002;165(1):1-9.
736 doi:10.1016/S0378-5955(02)00279-4
- 737 71. Anniko M, Wróblewski R. Ionic environment of cochlear hair cells. *Hear Res*. 1986;22(1):279-
738 293. doi:10.1016/0378-5955(86)90104-8
- 739 72. Forge A, Becker D, Casalotti S, Edwards J, Marziano N, Nevill G. Gap junctions in the inner ear:
740 comparison of distribution patterns in different vertebrates and assessment of connexin
741 composition in mammals. *J Comp Neurol*. 2003;467(2):207-231. doi:10.1002/cne.10916
- 742 73. Parra-Perez AM, Lopez-Escamez JA. Types of Inheritance and Genes Associated with Familial
743 Meniere Disease. *J Assoc Res Otolaryngol JARO*. Published online April 6, 2023.
744 doi:10.1007/s10162-023-00896-0

745